Compare ACDC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | DSGN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 853.8M |
| IPO Year | 2021 | 2021 |
| Metric | ACDC | DSGN |
|---|---|---|
| Price | $3.03 | $10.26 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.49 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 1.2M | 418.4K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,941,800,000.00 | N/A |
| Revenue This Year | $4.27 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $6.68 |
| 52 Week High | $8.22 | $17.25 |
| Indicator | ACDC | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 42.73 |
| Support Level | N/A | $9.83 |
| Resistance Level | $5.41 | $11.43 |
| Average True Range (ATR) | 0.43 | 0.62 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 14.26 | 33.24 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.